<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04925687</url>
  </required_header>
  <id_info>
    <org_study_id>1743714-2</org_study_id>
    <nct_id>NCT04925687</nct_id>
  </id_info>
  <brief_title>Pilot Study of Intravitreal Autologous CD34+ Stem Cell Therapy for Retinitis Pigmentosa</brief_title>
  <acronym>BMSCRP1</acronym>
  <official_title>A Pilot Study of the Feasibility and Safety of Intravitreal Autologous Bone Marrow CD34+ Stem Cell Therapy for Eyes With Vision Loss From Retinitis Pigmentosa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cures Within Reach</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this Phase 1 open-labeled prospective study, one eye of each participant with vision loss&#xD;
      from retinitis pigmentosa will be administered intravitreal injection of autologous CD34+&#xD;
      stem cells harvested from bone marrow. Each participant will be examined serially for 6&#xD;
      months after study injection to determine safety and feasibility of this intervention.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of intravitreal injection of autologous CD34+ cells</measure>
    <time_frame>6 months</time_frame>
    <description>Number and severity of Ocular and systemic adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility of intravitreal injection of autologous CD34+ cells</measure>
    <time_frame>Baseline</time_frame>
    <description>Number of CD34+ cells harvested for intravitreal injection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best corrected visual acuity</measure>
    <time_frame>6 months</time_frame>
    <description>Change in number of letters read in study eye from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best corrected visual acuity</measure>
    <time_frame>1 month</time_frame>
    <description>Change in number of letters read in study eye from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Field</measure>
    <time_frame>6 months</time_frame>
    <description>Change in visual field area in study eye from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Field</measure>
    <time_frame>1 month</time_frame>
    <description>Change in visual field area in study eye from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electroretinography</measure>
    <time_frame>6 months</time_frame>
    <description>Change in a and b wave amplitude in study eye from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electroretinography</measure>
    <time_frame>1 month</time_frame>
    <description>Change in a and b wave amplitude in study eye from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Eye Institute Vision Questionnaire</measure>
    <time_frame>6 months</time_frame>
    <description>Change in Vision Questionnaire compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Eye Institute Vision Questionnaire</measure>
    <time_frame>1 month</time_frame>
    <description>Change in Vision Questionnaire compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microperimetry</measure>
    <time_frame>6 months</time_frame>
    <description>Change in average threshold from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microperimetry</measure>
    <time_frame>6 months</time_frame>
    <description>Change percent reduced sensitivity from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microperimetry</measure>
    <time_frame>1 month</time_frame>
    <description>Change in average threshold from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microperimetry</measure>
    <time_frame>1 month</time_frame>
    <description>Change in percent reduced sensitivity from baseline</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">4</enrollment>
  <condition>Retinitis Pigmentosa</condition>
  <arm_group>
    <arm_group_label>Intravitreal autologous CD34+ cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravitreal injection of autologous CD34+ cells harvested from bone marrow under GMP conditions</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Intravitreal autologous CD34+ cells</intervention_name>
    <description>Autologous CD34+ cells harvested from bone marrow injected intravitreal</description>
    <arm_group_label>Intravitreal autologous CD34+ cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1. Age &gt;18 years of age 2. Visual Acuity at Presentation of 20/100 to Counting Fingers or&#xD;
        constriction of peripheral visual field 360 degrees to &lt;10 degrees by perimetry if BCVA is&#xD;
        better than 20/100, duration of vision loss &gt; 3 months 3. Vision loss due to retinitis&#xD;
        pigmentosa 4. The study eye has the worse visual acuity or peripheral constriction. 14.&#xD;
        Able and willing to sign consent 15. Able to keep follow-up appointments for at least 6&#xD;
        months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Other concurrent optic nerve or retinal disease in study eye affecting vision&#xD;
&#xD;
          2. History of active retinal or choroidal neovascularization or macular edema in study&#xD;
             eye requiring on-going intravitreal or periocular therapy in study eye&#xD;
&#xD;
          3. Active eye or systemic infection&#xD;
&#xD;
          4. Significant media opacity in the study eye precluding view of the fundus for&#xD;
             examination, photography or optical coherence tomography (OCT)&#xD;
&#xD;
        9. Other cause for vision loss in the study eye 10. History of coagulopathy or other&#xD;
        hematologic abnormality 11. Use of coumadin within 3 days of enrollment 12. Concurrent&#xD;
        immunosuppressive therapy 13. History of allergy to fluorescein dye&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susanna Park, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cynthia Wallace</last_name>
    <phone>916-7346303</phone>
    <email>clwallace@ucdavis.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Denise Macias</last_name>
    <phone>916-7346303</phone>
    <email>dcmacias@ucdavis.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jan Nolta, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gerhard Bauer</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mehrdad Abedi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ala Moshiri, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 2, 2021</study_first_submitted>
  <study_first_submitted_qc>June 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2021</study_first_posted>
  <last_update_submitted>August 19, 2021</last_update_submitted>
  <last_update_submitted_qc>August 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Davis</investigator_affiliation>
    <investigator_full_name>Susanna Park, MD, PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>retinitis pigmentosa</keyword>
  <keyword>stem cell</keyword>
  <keyword>retinal degeneration</keyword>
  <keyword>intravitreal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinitis</mesh_term>
    <mesh_term>Retinitis Pigmentosa</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

